Phase 1b Multicenter Open-label Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors
This study is testing two drugs called RMC-6291 and RMC-6236 in patients withadvanced KRASG12C-mutated solid tumors. The study team is trying to figure outthe right amount of each drug to give and how often to give it that has few sideeffects and is effective in treatment. The study has two parts: one where they startwith a small dose and gradually increase it to see how patients react, and anotherwhere they use the best dose they found in the first part with few side effects tosee if it works well. The study team will be very careful to make sure people staysafe throughout the study. They'll start with just a few patients and then decide ifthey can include more based on how things are going.
Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
This study is about testing a combination of drugs (gemcitabine, nab-paclitaxel, VS-6766, and defactinib) to treat a type of cancer called pancreatic ductal adenocarcinoma (PDAC). The study will be done in two parts, part A and Part B. In Part A, doctors will try to find the best dose of the combination of the drugs that can be given to a patient with out causing too many side effects (or referred to as dose-limiting toxicities). They will start with a low dose and gradually increase it as long as no side effects appear. They will also monitor patients closely for any side effects. In Part B, they will give more patients the best dosage of the combination of drugs they found in Part A to see if it works well to treat PDAC. The study will closely monitor for any side effects that patients may experience while taking the drugs.
Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
The objectives of this study are to evaluate the efficacy and safety of an oral medication, "ALXN2050", compared to placebo and establish an effective dose that addresses ongoing unmet medical need in patients with LN or IgAN who are treated with background standard of care.
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
The primary purpose of the study is to determine if accelerated BEP ((Bleomycin, Etoposide, and cisPlatin) is effective and tolerable for patients with advanced germ cell tumor compared to the standard treatment. We want to know if the accelerated chemotherapy using the same drugs is beneficial but not more toxic than the standard chemotherapy regimen. The accelerated chemotherapy is experimental.
Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
This study is looking at a new drug called ladarixin and how it works when given with a drug called sotorasib to treat advanced lung cancer. Ladarixin blocks something called CXCR1/2 which can help the immune system recognize cancer cells. Sotorasib is a type of medicine that has been FDA approved for use. It works by attaching to a specific part of a protein called KRASG12C, which is only present when the protein is not active. By attaching to this specific part of the protein, sotorasib can stop the protein from being active, which can help to slow down or stop the growth of cancer cells. The combination of ladarixin with sotorasib might help treat lung cancer with KRASG12C mutations better than sotorasib alone. The study will have two parts: Phase I and Phase II. In Phase I, the doctors will test different doses of the drugs to make sure they are safe and determine the best dose for use in Phase II. The treatment will be given in 21-day cycles and the drugs will be taken by mouth. Patients will be monitored for up to 2 years or until their cancer gets worse, they can't tolerate the treatment, or they decide to stop.
PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY
The purpose of the study is to evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M +Len) compared with rituximab in combination with lenalidomide (R+Len) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) who were treated with at least 1 prior systemic therapy. We want to compare M+Len to R+Len for overall survival rates, progression-free survival rates, compete response rates, and objective response rates. In the study, we want to identify biomarkers that are predictive of response to M+Len and can provide evidence of M + Len activity, or can increase the knowledge and understanding of diseasebiology.
Phenotypic and Genotypic Analysis of Keratoconus
This research study is being conducted to learn more about keratoconus, an eye disease, and to find possible genetic and biochemical changes that contribute to this disease. We hope to use this data to find changes that are involved in the development of, or risk for, keratoconus. The study will analyze DNA sequences of those affected with keratoconus and unaffected relatives of those who have a positive family history of keratoconus to study the causes of this condition so that better diagnosis and treatments may become available in the future.
Photodynamic Therapy for Macular Degeneration | NYU Langone Health
NYU Langone doctors can perform photodynamic therapy in conjunction with injections to manage wet macular degeneration.
Photopheresis for Cutaneous T-Cell Lymphoma | NYU Langone Health
NYU Langone doctors may use photopheresis to treat cutaneous T-cell lymphoma found in the blood.
Phototherapy & Laser Treatment for Vitiligo | NYU Langone Health
NYU Langone dermatologists use phototherapy and laser treatments to minimize the appearance of white patches caused by vitiligo.